Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

48.26 -0.90 (-1.83%)

Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

94 95 Next >

Deal Dispatch: Warner Bros., Bill.com, C3 AI—Key Auctions And Buyouts Shake The Market ↗

November 14, 2025

Paramount, Comcast, Netflix, Clearlake, Blackstone, and others drive major M&A activity. On the sell side are WBD, Bill.com and TuneIn.

Via Benzinga

Novo Nordisk Brings Back Former CEO To Lead Board ↗

November 14, 2025

Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday.

Via Stocktwits

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

Via MarketMinute

Why Did Scholar Rock Soar 26% Today? ↗

November 14, 2025

The company is planning to reapply for approval of a muscle atrophy therapy in the coming year.

Via Stocktwits

Topics Earnings

Ozempic Maker Novo Nordisk Faces Board Shakeup ↗

November 14, 2025

Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity drug market.

Via Benzinga

Is It Too Late to Buy Novo Nordisk After the Drop? ↗

November 14, 2025

Analysts still see 52% upside for Novo Nordisk -- find out whether its blockbuster drugs can spark a major rebound in 2025.

Via The Motley Fool

Why Is Everyone Talking About Novo Nordisk Stock? ↗

November 14, 2025

There is hardly a dull moment for the drugmaker these days.

Via The Motley Fool

Novo Nordisk Stock Falls Premarket As Investors Brace For Contentious Vote To Reinstate Former CEO ↗

November 14, 2025

The board overhaul follows mass resignations triggered by internal disputes over Novo’s direction.

Via Stocktwits

Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium ↗

November 13, 2025

Via Stocktwits

Korro Bio Early Trial Results Fall Short; Stock Hits New Low ↗

November 13, 2025

Korro Bio shares drop after KRRO-110 trial in AATD misses protein goals; company cuts 34% of staff and shifts focus to liver-targeted programs.

Via Benzinga

Pfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: Report ↗

November 13, 2025

CEO Albert Bourla told Yahoo Finance that the acquisition of GLP-1 maker Metsera is part of the company's "right to win" in the obesity drug game.

Via Stocktwits

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗

November 13, 2025

Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.

Via Benzinga

Mangoceuticals Shares Soar Pre-market After Partnering with Eli Lilly, Novo Nordisk To Sell Obesity Drugs ↗

November 13, 2025

The company has launched two programs, MangoRx Direct and PeachesRx Direct, to provide access to Lilly’s Zepbound and Novo’s Wegovy medicines.

Via Stocktwits

1 Incredible Reason to Buy LLY's Stock in November ↗

November 13, 2025

Eli Lilly struck a deal with President Donald Trump last week that could send the stock much higher.

Via The Motley Fool

Topics Government World Trade

Eli Lilly Soars: A Pharmaceutical Giant's Breakout Fueled by Blockbuster Drugs and Strategic Vision

November 12, 2025

INDIANAPOLIS, IN – November 12, 2025 – Eli Lilly and Company (NYSE: LLY) is experiencing a monumental stock breakout today, sending ripples across the global financial markets. The pharmaceutical...

Via MarketMinute

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗

November 12, 2025

Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.

Via Benzinga

Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch ↗

November 12, 2025

Eli Lilly to drop CVS Health's drug benefit plan and move to Rightway in 2026 as Novo Nordisk cuts Wegovy prices in India to defend market share.

Via Benzinga

Why Metsera's Share Price Is Plummeting This Week ↗

November 12, 2025

The biotech start-up's stock had been rising rapidly in 2025.

Via The Motley Fool

‘Somebody Knows Something:’ Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios ↗

November 11, 2025

Via Stocktwits

AMD, Oklo, AppLovin Corp, Viking Therapeutics And Novo Nordisk: Why These 5 Stocks Are On Investors' Radars Today ↗

November 11, 2025

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 inching up 0.2% to 6,846.61.

Via Benzinga

Topics Stocks

Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India ↗

November 11, 2025

Novo Nordisk shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 11, 2025

Via Benzinga

Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market? ↗

November 11, 2025

Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.

Via The Motley Fool

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion ↗

November 10, 2025

The final bid, at $10 billion, is expected to wrap up after Nov. 13 with the next shareholders' vote.

Via Investor's Business Daily

Topics Initial Public Offering

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

November 10, 2025

Via Benzinga

Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith ↗

November 09, 2025

Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.

Via Stocktwits

Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump ↗

November 09, 2025

The companies announced a huge deal that will have implications for investors.

Via The Motley Fool

Topics World Trade

Should You Buy Novo Nordisk After the Huge Investor Update? ↗

November 09, 2025

Pharma companies are under pressure to lower prices in the U.S.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

94 95 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

Headline News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today